The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial
Open accessAbstract
Background Bruton tyrosine kinase is a clinically validated target in mantle cell lymphoma. Acalabrutinib (ACP-196) is a highly selective, potent Bruton tyrosine kinase inhibitor developed to minimise off-target activity.Methods In this open-label, phase 2 study, oral acalabrutinib (100 mg twice per day) was given to patients with relapsed or refractory mantle cell lymphoma, until disease progression or unacceptable toxicity. The primary endpoint was overall response assessed according to the Lugano classification, and safety analyses were done in all participants. This trial is registered with ClinicalTrials.gov, number NCT02213926.Findings From March 12, 2015, to Jan 5, 2016, 124 patients with relapsed or refractory mantle cell lymphoma were enrolled and all patients received treatment; median age 68 years. Patients received a median of two (IQR 1-2) previous therapies. At a median follow-up of 15·2 months, 100 (81%) patients achieved an overall response and 49 (40%) patients achieved a complete response. The Kaplan-Meier estimated medians for duration of response, progression-free survival, and overall survival were not reached; the 12-month rates were 72% (95% CI 62-80), 67% (58-75), and 87% (79-92%), respectively. The most common adverse events were primarily grade 1 or 2 and were headache (47 [38%]), diarrhoea (38 [31%]), fatigue (34 [27%]), and myalgia (26 [21%]). The most common grade 3 or worse adverse events were neutropenia (13 [10%]), anaemia (11 [9%]), and pneumonia (six [5%]). There were no cases of atrial fibrillation and one case of grade 3 or worse haemorrhage. The median duration of treatment was 13·8 months. Treatment was discontinued in 54 (44%) patients, primarily due to progressive disease (39 [31%]) and adverse events (seven [6%]).Interpretation Acalabrutinib treatment provided a high rate of durable responses and a favourable safety profile in patients with relapsed or refractory mantle cell lymphoma. These findings suggest an important role for acalabrutinib in the treatment of this disease population.Funding Acerta Pharma, a member of the AstraZeneca Group.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As such, ibrutinib and the more selective BTK inhibitor acalabrutinib 39 have shown beneficial effects in patients with MCL and have received US Food and Drug Administration approval for this indication.”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [39]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Revised response criteria for malignant lymphoma.
Cheson, B. D., Pfistner, B., Juweid, M., Gascoyne, R., Specht, L., Horning, S., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,537
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Interpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B. C.-Y., & Pater, J. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 3,016
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306220 · Cited by 1,685
Self-citationAcalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Harrington, B. K., O'Brien, S. M., Jones, J. A., Schuh, A., Devereux, S., Chaves, J. M., Wierda, W. G., Awan, F. T., Brown, J. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509981 · Cited by 916
Ponader, S., Chen, S.-S., Buggy, J. J., Balakrishnan, K., Gandhi, V., Wierda, W. G., Keating, M. J., O'Brien, S., Chiorazzi, N., & Burger, J. A. (2012) · Blood · doi:10.1182/blood-2011-10-386417 · Cited by 640
de Rooij, M. F. M., Kuil, A., Geest, C. R., Eldering, E., Chang, B. Y., Buggy, J. J., Pals, S. T., & Spaargaren, M. (2012) · Blood · doi:10.1182/blood-2011-11-390989 · Cited by 558
Barf, T. A., Covey, T. M., Izumi, R. E., van de Kar, B., Gulrajani, M., van Lith, B., Hoek, M. E.-V., de Zwart, E., Mittag, D., Demont, D., et al. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.242909 · Cited by 399
Cheah, C. Y., Seymour, J. F., & Wang, M. L. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.5904 · Cited by 276
Cited by
Sorted by citations
Items 401–461 of 461
Mautone, L., Dierlamm, J., Heinrich, M., Viehweger, F., Schäfer, H., Schüttauf, F., Green, S., & Dulz, S. (2023) · Laryngo-Rhino-Otologie · doi:10.1055/a-2109-6646
Novo, M., & Savelli, C. B. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00019-6
Acute leukemias and complicated lymphomas: pearls to optimize management when patients stay local
Patel‐Donnelly, D., & Gandhi, M. D. (2023) · Hematology · doi:10.1182/hematology.2023000430
Silkenstedt, E., Dreyling, M. H., & Rule, S. A. (2023) · Springer eBooks · doi:10.1007/978-3-031-22881-0_11
Poh, C., & Smith, S. D. (2023) · doi:10.1002/9781119823193.ch36
Cavallo, F., Clerico, M., Lucchini, E., Castiglione, A., Re, A., Zilioli, V. R., Visco, C., Tani, M., Olivieri, J., Arcaini, L., et al. (2024) · British Journal of Haematology · doi:10.1111/bjh.19617
Zyryanov, S. K., & Dyakov, I. N. (2024) · FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology · doi:10.17749/2070-4909/farmakoekonomika.2024.259
Phillips, T. J. (2024) · The Hematologist · doi:10.1182/hem.v21.5.202455
Lee, B. J., Liu, J., Griffin, S. P., Doh, J., Ciurea, S. O., Kongtim, P., & Brem, E. A. (2024) · Cancer Medicine · doi:10.1002/cam4.70310
Prognostic risk factors of pneumonia associated with COVID-19 in patients with lymphoma
Liu, D., Xia, Y. Y., Wang, H. Z., Xing, L., Li, P., Wei, H., Ma, J., He, Q., Xie, L., Lu, K., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2024.1504809
Relapsed or Refractory Mantle Cell Lymphoma: Available and Emerging Therapies
Champagne, J., & Villa, D. R. (2024) · Canadian Hematology Today · doi:10.58931/cht.2024.3356
Koshkina, U. G., Tumyan, G. S., Semenova, A., Кичигина, М. Ю., Заводнова, И. З., Тупицына, Д. Н., Парамонова, Е. В., Антипова, А. С., Олеговна, Ш. В., Ключагина, Ю. И., et al. (2025) · Clinical oncohematology · doi:10.21320/2025-18-2-121-133
Stellenwert neuer Therapiemodalitäten beim Mantelzelllymphom
Jachimowicz, R. D., & Dreyling, M. H. (2025) · Die Onkologie · doi:10.1007/s00761-025-01710-7
Deng, L., Song, Y., Zhou, K., Li, D., Hu, J., Zou, D., Gao, S., Yang, H., Zhang, H., Ji, J., et al. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03202-x
Therapy Sequencing in Relapsed/Refractory MCL
Giné, E. (2025) · Hematological Oncology · doi:10.1002/hon.70074
Aggressive non-Hodgkin and Burkitt lymphomas
Rosenthal, A. C. (2025) · doi:10.1182/ashsap9.chapter45
Patel, K. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/s2152-2650(25)00362-3
Matsumura, N., & Mandai, M. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02879-y
Piron, B., & Tessoulin, B. (2025) · Bulletin du Cancer · doi:10.1016/j.bulcan.2025.10.004
Jiang, C., Lee, W., Zhang, T., Jordan, A. A., Yan, F., Cai, Q., McIntosh, J. M., Vargas, J., Liu, Y., & Wang, M. L. (2024) · Figshare · doi:10.6084/m9.figshare.26054664
Yan, F., Jiang, C., Jordan, A. A., Che, Y., Liu, Y., Cai, Q., Xue, Y., Li, Y., McIntosh, J. M., Chen, Z., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26678081
Jiang, C., Lee, W., Zhang, T., Jordan, A. A., Yan, F., Cai, Q., McIntosh, J. M., Vargas, J., Liu, Y., & Wang, M. L. (2024) · Figshare · doi:10.6084/m9.figshare.26735616
Jiang, C., Lee, W., Zhang, T., Jordan, A. A., Yan, F., Cai, Q., McIntosh, J. M., Vargas, J., Liu, Y., & Wang, M. L. (2024) · Figshare · doi:10.6084/m9.figshare.26735625
Jiang, C., Lee, W., Zhang, T., Jordan, A. A., Yan, F., Cai, Q., McIntosh, J. M., Vargas, J., Liu, Y., & Wang, M. L. (2024) · Figshare · doi:10.6084/m9.figshare.26054810
Yan, F., Jiang, C., Jordan, A. A., Che, Y., Liu, Y., Cai, Q., Xue, Y., Li, Y., McIntosh, J. M., Chen, Z., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26678078
Jiang, C., Lee, W., Zhang, T., Jordan, A. A., Yan, F., Cai, Q., McIntosh, J. M., Vargas, J., Liu, Y., & Wang, M. L. (2024) · Figshare · doi:10.6084/m9.figshare.26735622
Yoon, D. H., Cao, J., Chen, T.-Y., 伊豆津宏二, Kim, S. J., Kwong, Y. L., Lin, T. Y., Thye, L. S., Xu, B., Yang, D. H., et al. (2020) · Figshare · doi:10.6084/m9.figshare.11998545
Jiang, C., Lee, W., Zhang, T., Jordan, A. A., Yan, F., Cai, Q., McIntosh, J. M., Vargas, J., Liu, Y., & Wang, M. L. (2024) · Figshare · doi:10.6084/m9.figshare.26735619
Yan, F., Jiang, C., Jordan, A. A., Che, Y., Liu, Y., Cai, Q., Xue, Y., Li, Y., McIntosh, J. M., Chen, Z., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26678084
Yan, F., Jiang, C., Jordan, A. A., Che, Y., Liu, Y., Cai, Q., Xue, Y., Li, Y., McIntosh, J. M., Chen, Z., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26678075
Yan, F., Jiang, C., Jordan, A. A., Che, Y., Liu, Y., Cai, Q., Xue, Y., Li, Y., McIntosh, J. M., Chen, Z., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26678072
Koroleva, D. A. (2025) · Clinical oncohematology · doi:10.21320/2500-2139-2025-18-4-forum
Lee, C.-L., Kuo, C.-Y., Ma, M., Liu, H.-L., Chiu, L.-J., Liao, P.-H., & Wang, M.-C. (2026) · Journal of Cancer Research and Practice · doi:10.4103/ejcrp.ejcrp-d-25-00024
Zhang, Y., Nie, M., Cao, Y., Li, Z., Huang, H., Li, G., Sun, X., Liu, P., Gao, Y., Fang, X., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-71241-1
PRMT5 inhibition sensitizes B-cell lymphoma cells to ferroptosis
Liu, Y., Chen, R., Gao, X., Zhu, F., Ni, Q., Bates, P. D., Wu, S., Zai, Z., Obernberger, V. A., Weerawardhene, K., et al. (2026) · Leukemia · doi:10.1038/s41375-026-02932-3
Dissecting Pirtobrutinib Resistance in Mantle Cell Lymphoma Through Single‐Cell Multi‐Omics
Yan, F., Liu, Y., Lee, H. J., Wang, W., McIntosh, J. M., Li, Y., Vargas, J., Fei, Y., Ahmed, S., Simon, L. M., et al. (2026) · American Journal of Hematology · doi:10.1002/ajh.70304
Wang, Y., Larson, M. C., Hwang, S. R., Villa, D. R., Kugathasan, L., Kumar, A. A., Joseph, A., Brooks, T., Hill, B. T., Bond, D. A., et al. (2026) · Blood Cancer Journal · doi:10.1038/s41408-026-01507-w
Modern Management of Mantle Cell Lymphoma
Tix, T., Kumar, A. A., Eyre, T. A., & Dreyling, M. H. (2026) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-26-517468
Epstein-Barr virus associated diseases: Immune alterations and targeted approaches
Cao, S., Xiong, J., Zhao, J., & Zhao, W.-L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1794394
End of transplantation's reign in mantle cell lymphoma
Trotman, J., & Falconer, J. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00556-8
Molecular Insights and Novel Therapies for Lymphoproliferative Disorders
Wan, S., & Naik, S. G. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27115026
Kawczak, P., & Bączek, T. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15124425
Bagde, P. H., Deb, B., Shrivastava, H., & Jha, H. C. (2026) · Springer eBooks · doi:10.1007/978-981-95-9777-2_13
First-Line Bruton’s Tyrosine Kinase Inhibitor-Based Regimens for Mantle Cell Lymphoma
Puckrin, R., Villa, D. R., Fleury, I., Larouche, J.-F., & Kuruvilla, J. G. (2026) · Current Oncology · doi:10.3390/curroncol33070426
Giebel, S., Czyż, A., Hus, I., Gil, L., Giannopoulos, K., Romejko‐Jarosińska, J., Majcherek, M., Szeremet, A., Wache, A., Kwaśnik, P., et al. (2026) · Annals of Hematology · doi:10.1007/s00277-026-07178-8
Samperio, V. M., Hamoud, M., Ike, I., & Dasanu, C. A. (2026) · European Journal Of Haematology · doi:10.1111/ejh.70272
How soon is now for new treatments for mantle cell lymphoma?
Martin, P. (2026) · Blood · doi:10.1182/blood.2026034444
Tedeschi, A., Barocelli, F., Gerra, L., Breviario, F., Sbarra, F., Pagnoni, G., Marasacchia, G., Marangi, F., Darroudi, S., Spigno, F. D., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15166160
Baccon, D., Zhou, J., Atallah‐Yunes, S. A., Wang, J., Hwang, S. R., Paludo, J., Munoz, J. L., Iqbal, M., Breen, W. G., Lester, S. C., et al. (2026) · Blood Neoplasia · doi:10.1016/j.bneo.2026.100283
Shao, J., Peng, H., Zhou, L., Liu, L., Ma, X., Zhang, X., Li, Z., & Li, S. (2026) · Patient · doi:10.1007/s40271-026-00836-z
BTK Inhibitors for the Treatment of Mantle Cell Lymphoma—Current Status and Perspectives
Robak, T., Wolska, A., & Robak, P. J. (2026) · Cancers · doi:10.3390/cancers18162698
Chan, W. L., Chng, W. J., & Li, Q.-J. (2026) · Biomarker Research · doi:10.1186/s40364-026-00985-1
EXABS-233-MCL: Maximizing the Role of BTK Inhibition in MCL
Wang, Y. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/s2152-2650(26)00345-9
Malhotra, P., Bhurani, D., Sengar, M., Sood, N., Nag, A., Aribandi, A., George, B., Menon, H., Bhattacharyya, J., Kalashetty, M., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1822178
Improving survival and narrowing age disparities in mantle cell lymphoma across therapeutic eras
Munir, M., Vaughn, J. L., Rimmalapudi, S., & Epperla, N. (2026) · Blood Cancer Journal · doi:10.1038/s41408-026-01648-y
Targeted Cytotoxic Enzyme Inhibitors
Serdoura, M. (2026) · Advances in computational intelligence and robotics book series · doi:10.4018/979-8-3373-6551-0.ch006
BindingDB Entry 50016732: The Ascension of Targeted Covalent Inhibitors.
BindingDB (2023) · UC San Diego · doi:10.7270/q23f4tpf
Metadata
- Authors
- Wang, M., Rule, S., Zinzani, P. L., Goy, A., Casasnovas, O., Smith, S. D., Damaj, G., Doorduijn, J., Lamy, T., Morschhauser, F., Panizo, C., Shah, B., Davies, A., Eek, R., Dupuis, J., Jacobsen, E., Kater, A. P., Le Gouill, S., Oberic, L., Robak, T., Covey, T., Dua, R., Hamdy, A., Huang, X., Izumi, R., Patel, P., Rothbaum, W., Slatter, J. G., & Jurczak, W.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- University of Plymouth (GB)
- University of Bologna (IT)
- Hackensack University Medical Center (US)
- Inserm (FR)
- University of Washington (US)
- Centre Hospitalier Universitaire de Caen Normandie (FR)
- Erasmus MC (NL)
- Centre Hospitalier Universitaire de Rennes (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- Clinica Universidad de Navarra (ES)
- Moffitt Cancer Center (US)
- Cancer Research UK (GB)
- Centre Hospitalier Universitaire Henri-Mondor (FR)
- Harvard University (US)
- Amsterdam UMC Location University of Amsterdam (NL)
- Jagiellonian University (PL)
- Corresponding author
- Wang, Michael
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2018-02
- Volume
- 391
- Issue
- 10121
- Pages
- 659-667
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC7864374
- OpenAlex
- W2774522106
- Cited by
- 453
- References
- 23
- Citations by year
- 2026: 39 · 2025: 31 · 2024: 51 · 2023: 49 · 2022: 59 · 2021: 60 · 2020: 63 · 2019: 64 · 2018: 34
- FWCI
- 34.80
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- PEARL (University of Plymouth) (submittedVersion, other-oa)
- Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
- Jagiellonian University Repository (Jagiellonian University) (submittedVersion, cc-by-nc-nd)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- HAL (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by-nc-nd)
- ePrints Soton (University of Southampton) (submittedVersion)
- PEARL (University of Plymouth) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Funders
- AstraZeneca
- University of Texas MD Anderson Cancer Center
- National Cancer Institute (P30CA076292)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Clinical Neurology › CNS Lymphoma Diagnosis and Treatment
- Keywords
- acalabrutinib, mantle cell lymphoma, relapsed/refractory lymphoma, BTK inhibitors, overall response rate, complete response, progression-free survival, overall survival, adverse events, neutropenia, drug safety, oral targeted therapy, treatment durability, hemorrhage
- MeSH terms
- Aged, Benzamides, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Pyrazines, Recurrence, Survival Analysis, Treatment Outcome, Lymphoma, Mantle-Cell, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
